Ablaris Therapeutics, Inc. is majority-owned and operated by Arrowhead Research Corporation. For more information about Ablaris' anti-obesity drug candidate, Adipotide^®, Ablaris' first therapeutic to undergo clinical testing and the Homing Peptide™ technology platform, please visit Arrowhead's website at www.arrowheadresearch.com.